Severity of Prior COVID-19 Infection is Associated with Postoperative Outcomes Following Major Inpatient Surgery

Nathaniel B. Verhagen¹, Gopika SenthilKumar^{1,2}, Taylor Jaraczewski¹, Nicolas K.
Koerber¹, Jennifer R. Merrill¹, Madelyn A. Flitcroft¹, Aniko Szabo³, Anjishnu Banerjee³,
Xin Yang⁴, Bradley W. Taylor⁴, Carlos E. Figueroa Castro⁵, Tina W.F. Yen¹, Callisia N.
Clarke¹, Kathryn Lauer⁶, Kurt J. Pfeifer⁷, Jon C. Gould⁸, Anai N. Kothari^{1,4}; on behalf of
the N3C Consortium

- ¹Department of Surgery, Division of Surgical Oncology, Medical College of Wisconsin,
 Milwaukee, WI
- ²Department of Physiology and Anesthesiology, Medical College of Wisconsin,
 Milwaukee, WI
- ³Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI
- ⁴Clinical and Translational Science Institute of Southeastern Wisconsin, Medical College
 of Wisconsin, Milwaukee, WI
- ⁵Department of Medicine, Division of Infectious Diseases, Medical College of Wisconsin,
 Milwaukee, WI
- ⁶Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI
- ⁷Department of Medicine, Section of Perioperative & Consultative Medicine, Medical
 College of Wisconsin, Milwaukee, WI
- ⁸Department of Surgery, Division of Minimally Invasive and GI Surgery, Medical College
 of Wisconsin, Milwaukee, WI
- 22

23

24 Corresponding Author:

- 25 Anai N. Kothari, MD MS FSSO
- 26 Medical College of Wisconsin
- 27 Division of Surgical Oncology
- 28 8701 W Watertown Plank Road
- 29 Milwaukee, Wisconsin 53226, USA
- 30 (414)955-1443
- 31 <u>akothari@mcw.edu</u>

32 ABSTRACT

33	Objective: To determine the association between severity of prior history of SARS-
34	CoV-2 infection and postoperative outcomes following major elective inpatient surgery.
35	Summary Background Data: Surgical guidelines instituted early in the COVID-19
36	pandemic recommended delay in surgery up to 8 weeks following an acute SARS-CoV-
37	2 infection. Given that surgical delay can lead to worse medical outcomes, it is unclear if
38	continuation of such stringent policies is necessary and beneficial for all patients,
39	especially those recovering from asymptomatic or mildly symptomatic COVID-19.
40	Methods: Utilizing the National Covid Cohort Collaborative (N3C), we assessed
41	postoperative outcomes for adults with and without a history of COVID-19 who
42	underwent major elective inpatient surgery between January 2020 and February 2023.
43	COVID-19 severity and time from SARS-CoV-2 infection to surgery were each used as
44	independent variables in multivariable logistic regression models.
45	Results: This study included 387,030 patients, of which 37,354 (9.7%) had a diagnosis
46	of preoperative COVID-19. History of COVID-19 was found to be an independent risk
47	factor for adverse postoperative outcomes even after a 12-week delay for patients with
48	moderate and severe SARS-CoV-2 infection. Patients with mild COVID-19 did not have
49	an increased risk of adverse postoperative outcomes at any time point. Vaccination
50	decreased the odds of mortality and other complications.
51	Conclusions: Impact of COVID-19 on postoperative outcomes is dependent on
52	severity of illness, with only moderate and severe disease leading to higher risk of
53	adverse outcomes. Existing wait time policies should be updated to include
54	consideration of COVID-19 disease severity and vaccination status.

55 **INTRODUCTION**

As of February 2023, over 100 million cases of SARS-CoV-2 infections have been reported in the US¹. Among those with prior infection, 15–20% will require elective surgery². Prior history of COVID-19 infection is associated with adverse postoperative outcomes and complications³⁻⁶, and this risk can persist up to eight weeks after infection⁵. Accordingly, early in the pandemic, several groups recommended a delay in surgery for 7–8 weeks following a COVID-19 infection^{5,7}.

While these guidelines attempted to mitigate the risk of COVID-19 by delaying surgery, as the pandemic transitions to an endemic phase, there is a paucity of data to guide the de-implementation of these policies. This is especially important when also considering that delaying care can worsen both short- and long-term health outcomes⁸. In addition, delayed surgical care can lead to prolonged poor quality of life including chronic pain, impaired mobility, and inability to work.

The severity of a SARS-CoV-2 infection can vary widely from mild flu-like symptoms or 68 69 no symptoms to systemic disease requiring hospitalization and even critical care. Most 70 current guidelines for managing COVID-19 in the perioperative setting are not stratified 71 by disease severity; however, there appears to be a relationship between severity of infection and postoperative outcomes⁸. Prior studies also show that compared to those 72 73 with asymptomatic or mild disease, postoperative intensive care unit stay is higher among those with severe COVID-19 who require hospitalization⁹. This suggests that 74 75 including severity of SARS-CoV-2 infection in surgical wait time guidelines may facilitate more personalized patient recommendations and prevent unnecessary delays to 76

surgery for those with less severe infections. In addition, since disease severity can be
lowered through vaccination², and as of February 2023, over 269 million people in the
US received at least 1 dose of COVID-19 vaccine¹, the impact of preoperative
vaccination among patients who present with COVID-19 prior to requiring surgery must
be taken into consideration.

The primary objective of this study was to measure the association between the severity of SARS-CoV-2 infection prior to major elective surgery and postoperative adverse outcomes. Secondary objectives included investigating how severity should be considered in surgical wait time guidelines and the influence of vaccination on postoperative outcomes.

87 METHODS

88 Electronic health record data from the National COVID Cohort Collaborative (N3C), the 89 largest multi-site centralized data source of COVID-19 patients in the United States, 90 was retrospectively analyzed using the N3C Data Enclave. PCORnet, TriNetX, OMOP, 91 and ACT are the primary data sources that contribute to N3C. A detailed description of 92 the N3C's rationale, design, infrastructure, and deployment has been previously 93 reported. Patients 18 years and older who underwent major inpatient surgery between 94 January 2020 and February 2023 were included, and the surgical procedures were selected based on prior literature assessing the role of COVID-19 on surgical 95 outcomes⁵. The following were included: hip arthroplasty, knee arthroplasty, 96 97 laminectomy, spinal arthrodesis, craniectomy, aortic aneurysm repair, lung excision,

98 coronary artery bypass graft, esophagectomy, mastectomy, prostatectomy, colectomy, 99 gastrectomy, hepatectomy, and pancreatectomy (Supplemental Table 1). 100 Patient characteristics (sex, age, race and ethnicity, Charlson Comorbidity Index)¹¹, 101 were identified using the N3C's Shared Knowledge Store patient fact table. Standard 102 SNOMED codes from the Observational Health Data Science and Informatics' (OHDSI) 103 ATLAS tool were used to identify elective inpatient procedures and patients' 104 comorbidities (Supplemental Table 1,2). Exclusion criteria included undergoing natural 105 orifice, percutaneous, endoscopic, diagnostic (unless open surgery), or transplant 106 procedures. For patients with multiple surgeries, the first surgery after SARS-CoV-2 107 infection was used. 108 COVID-19 positivity was defined as having a positive lab measurement (PCR or 109 antigen) or a positive COVID-19 diagnosis (ICD10-CM code U07.1) any time before 110 surgery. Patients with COVID-19 within 24 hours of surgery were excluded. The severity 111 of a patient's COVID-19 was determined using the World Health Organization's (WHO) Clinical Progression Scale (CPS)¹¹. Patient-specific severity was obtained from the N3C 112 113 Knowledge Store and derived from critical visits associated with COVID positivity. Mild

severity was defined as having outpatient visit only (WHO Severity 1–3). Moderate

115 severity was defined as requiring hospitalization without pulmonary support (WHO

116 Severity 4–6). Severe disease was defined as needing hospitalization with

117 extracorporeal membrane oxygenation (ECMO or invasive ventilation, WHO Severity 7-

118 9)¹². The N3C Knowledge Store was used to determine the vaccination status of

119 patients. Fully vaccinated patients were defined as having either received a single dose

120 of the viral vector vaccine or two doses of mRNA vaccine at least 14 days before their

first SARS-CoV-2 infection. Patients who received only one dose of the mRNA vaccine
or were vaccinated after a COVID-19 diagnosis were not considered fully vaccinated.

123 The primary outcome of the study was a 30-day composite adverse postoperative event 124 and included the following: mortality, unplanned readmission, acute myocardial 125 infarction, cardiac arrhythmia, deep vein thrombosis, pneumonia, pulmonary embolism, 126 renal failure, respiratory failure, sepsis, and urinary tract infection. Each individual 30-127 day complication included in the composite outcome was also separately evaluated. 128 Outcomes were constructed using SNOMED codes and concepts associated with 129 chronic conditions or directly caused by COVID-19 were excluded (Supplemental Table 130 3).

131 Unadjusted baseline characteristics and comparisons between patients with and without 132 prior COVID-19 were analyzed using standard descriptive statistics. Adjusted analyses 133 were performed using multivariable logistic regression models. Separate models were fit 134 for each outcome with covariates that included age, sex, race and ethnicity, Charlson 135 Comorbidity Index (CCI), and relative surgical risk. Relative surgical risk is a computed 136 feature based on the expected median length of stay for a given procedure. Additional 137 logistic regression models were fit to measure the association between 30-day 138 postoperative adverse outcomes and (1) time between SARS-CoV-2 infection and 139 surgery, (2) disease severity, and (3) vaccination status. Within each disease severity 140 group, the risk of 30-day postoperative adverse outcomes as a factor of time between 141 infection and surgery was analyzed. All analysis were conducted using the N3C Data 142 Enclave using the tidyverse, ggplot2, gtsummary, splines, and broom R packages.

143 **RESULTS**

- 144 387,030 patients were included in the study and 37,354 (9.7%) had a preoperative
- 145 diagnosis of COVID-19. Table 1 details baseline patient demographics and
- 146 characteristics in those with and without a history of COVID-19.
- 147 History of COVID-19 and 30-day postoperative adverse outcomes
- 148 On unadjusted analysis, rate of 30-day postoperative adverse events was greater in
- patients with a history of COVID-19 than those without (22.7% vs. 21.5%, P<0.001,
- 150 Table 1). Additionally, the rates of 30-day mortality (1.8% vs. 1.4%), postoperative
- 151 pulmonary embolism (1.4% vs. 1.2%; P=0.008), renal failure (6.9% vs. 6.4%; P<0.001),
- 152 sepsis (3.2% vs. 2.9%; P=0.007), and composite non-fatal event (22% vs. 21%;
- 153 P<0.001) were all significantly greater in patients with a history of COVID-19 (Table 1).
- 154 Following adjustment for age, sex, race, ethnicity, smoking status, comorbid disease,
- and relative risk of surgery, patients with a history of COVID-19 had greater odds of 30-
- day composite adverse postoperative events (aOR 1.09 [1.06–1.12]; Figure 1).
- 157 Association of time between SARS-CoV-2 infection and surgery and 30-day
- 158 postoperative adverse outcomes
- 159 Patients were stratified based on timing of surgery relative to SARS-CoV-2 infection.
- 160 Groups included 0–4 weeks (N=7,425, 19.9%), 4–8 weeks (N=3,936, 10.5%), 8–12
- 161 weeks (N=2,604, 7.0%) and 12+ weeks (N=23,389, 62.6%). Patients who underwent
- 162 surgery 0–4 weeks after COVID-19 had overall higher rates of postoperative adverse
- events, including mortality (3.3% vs. 1.4%; P<0.001) and any non-fatal complications

164 (26% vs. 21%, P<0.001), when compared to patients without COVID-19 (Supplemental

- 165 Table 4). On adjusted analysis (Figure 2, Supplemental Table 5), patients who
- 166 underwent surgery within 4 weeks of SARS-CoV-2 infection had increased odds of 30-
- 167 day postoperative composite adverse event (aOR 1.27 [1.20–1.35]), mortality (aOR
- 168 2.34 [2.05–2.67]), deep vein thrombosis (aOR 1.33 [1.12–1.57]), pneumonia (aOR 1.60
- 169 [1.43–1.79]), pulmonary embolism (aOR 1.44 [1.20–1.70]), renal failure (aOR 1.28
- 170 [1.17–1.39]), respiratory failure (aOR 1.53 [1.40–1.66]), and sepsis (aOR 1.52 [1.36–
- 171 1.69]). The odds of composite adverse postoperative outcome returned to baseline at
- 172 12 weeks following infection (aOR 1.01 [0.98–1.05] at 12+ weeks).
- Association of severity of SARS-CoV-2 infection and 30-day postoperative adverse
- 174 outcomes

Patients were next stratified based on the severity of their SARS-CoV-2 infection prior to surgery, and 31,677 (84.8%), 5,009 (13.4%), and 655 (1.8%) patients had mild,

177 moderate, and severe disease, respectively. Incidence of adverse 30-day postoperative

178 outcomes increased with severity across all measured outcomes (Supplemental Table

179 6), and patients with severe disease had the highest rate of mortality (14% vs. 1.4%),

any non-fatal complication (60% vs. 21%), and hospital readmission (18% vs. 11%)

181 when compared to patients without COVID-19 history (P<0.001 all). After adjusting for

182 patient demographics, risk of surgery, and comorbidities, patients with moderate and

183 severe disease had higher odds for all assessed adverse events except for pulmonary

embolism for moderate COVID-19 (aOR 1.19 [0.96–1.45]) and hospital readmission for

severe COVID-19 (aOR 1.20 [0.98–1.46]) (Figure 3, Supplemental Table 7).

The interplay between timing of surgery and COVID-19 disease severity in influencing risk for 30-day composite postoperative complications

188 For each COVID-19 severity group (mild, moderate, severe), the adjusted odds of 189 having a composite adverse postoperative event were measured (Figure 4). Patients 190 with mild COVID-19 infections did not demonstrate an increased risk, regardless of the 191 time between infection and surgery. Patients with moderate disease were observed to 192 have increased risk for composite adverse events at 0-4 weeks (aOR 1.84 [1.61-2.10]) 193 that persisted beyond 12 weeks between COVID-19 and surgery (aOR 1.36 [1.25-194 1.48]) when compared to patients without prior history of COVID-19. The magnitude of 195 risk was greater for patients with severe disease, with highest odds for an adverse 196 event occurring if surgery was performed within 4 weeks of SARS-CoV-2 infection (aOR 197 8.41 [6.42–11.1]). This risk did decrease with time, though it remained elevated when 198 compared to patients who did not have prior COVID-19 (aOR 2.22 [1.66-2.95] at 12+ 199 weeks).

200 Preoperative vaccination and 30-day postoperative adverse outcomes

In patients with COVID-19 prior to surgery, vaccination significantly decreased rates of
pneumonia (2.3% vs. 3.0%; P=0.003), respiratory failure (4.2% vs. 5.6%; P<0.001), and
sepsis (2.7% vs. 3.3%; P<0.05) (Supplemental Table 8). After adjustment for patient
demographics, comorbidities, and relative risk of surgery, vaccination was associated
with decreased odds of mortality (aOR 0.76 [0.59–0.95]), pneumonia (aOR 0.73 [0.60–
0.88]), respiratory failure (aOR 0.72 [0.62–0.83]), and sepsis (aOR 0.79 [0.66–0.94])
(Figure 5).

208 **DISCUSSION**

209 In this study, we aimed to understand how the severity of a SARS-CoV-2 infection prior 210 to major elective inpatient surgery influences postoperative outcomes using the N3C 211 Data Enclave—a harmonized electronic health data platform comprising over 70 institutions and more than 18,000,000 patients¹⁰. Our findings demonstrate that a prior 212 213 history of COVID-19 is an independent risk factor for adverse surgical outcomes, and 214 the risk remains elevated for 12 weeks after a SARS-CoV-2 infection; however, this is 215 dependent on the severity of COVID-19. Patients with mild disease (not requiring 216 hospitalization) did not have an elevated risk of adverse outcomes regardless of the 217 timing of surgery. Those with moderate and severe disease had persistently elevated 218 surgical risk that lasted 12+ weeks after an acute infection.

219 The results of this study are consistent with prior work examining surgical outcomes in 220 patients with a history of SARS-CoV-2 infection conducted early in the pandemic. The 221 COVIDSurg Collaborative, a multinational collaborative that aimed to explore the impact 222 of COVID-19 in surgical patients and services, published the first population-level study 223 assessing surgical outcomes following a SARS-CoV-2 infection. They found an 224 increased risk of surgical mortality that lasted for 7 weeks following an acute infection⁴. 225 Another large-scale study by Deng and colleagues confirmed these findings in a United 226 States population and advocated for a wait time of 8 weeks from the time of a SARS-227 CoV-2 infection before proceeding with elective surgery⁵. In response to these data 228 (and other similar findings from single institution series), expert guidelines suggested 229 delaying elective surgery 7 weeks while weighing the time-sensitivity of the intervention¹³. These studies and guidelines were crucial given the novel situation 230

perioperative providers were faced with early in the COVID-19 pandemic as an
 increasing number of patients with prior SARS-CoV-2 infection required elective
 surgery.

234 Still, several gaps remain in the evidence base for guiding the management of this 235 patient population which are now addressed by this study. We re-demonstrate the risk 236 for adverse 30-day composite postoperative outcomes remains elevated for 8 weeks 237 after a SARS-CoV-2 infection; however, when stratified by severity, this risk only is 238 present in those recovered from moderate and severe infections (anyone who required 239 hospitalization). Those with mild disease were not at increased risk of composite 240 adverse outcomes even when undergoing surgery within 4 weeks of an acute infection which is consistent with prior work⁸. We also provide a more detailed measurement of 241 242 the association across a spectrum of specific postoperative complications. For example, 243 patients with mild disease had no increased odds for all assessed adverse events, 244 moderate disease showed elevated risk for all assessed complications, while those with 245 severe disease had increased odds of all assessed complications with a magnitude of 246 effect multiple-fold greater. This study also provides evidence that vaccination can 247 reduce the risk of adverse postoperative events in patients with a prior history of 248 COVID-19.

The data presented in this study include patients who underwent surgery prior to March 2023 and thus reflects the current environment as the pandemic shifts to an endemic phase. As a comparison, data collected for the COVIDSurg study was in October of 2020, and the Deng et al. study of patients in the United States included surgeries performed until June of 2021. Equipped with the updated data presented in this study, 254 we propose the following guidance for managing patients prior to inpatient elective 255 surgery. First, all patients who are planned to undergo surgery should be assessed for 256 their history of COVID-19, including detailed information regarding the severity of their 257 infection. Those with a prior history should be classified as having either 258 asymptomatic/mild disease or moderate/severe disease. After this determination is 259 made, patients with asymptomatic/mild disease should have their surgery delayed at 260 least 5 days from the time of positive test to ensure they do not develop progressive 261 symptoms that increase the severity of illness. If they remain asymptomatic/mild after 262 this wait time, our data supports the safety of proceeding with elective surgery. 263 However, if the patient has moderate/severe disease or develops moderate/severe 264 disease, then consideration should be made for delaying surgery while also considering 265 the risk/benefit ratio of potential harms related to a prolonged delay in circumstances of 266 time-sensitive surgical indications. Since we do not observe a return to baseline risk 267 even beyond 12 weeks in patients with moderate/severe disease, no standard time for 268 delay can be recommended. Instead, we advocate for early engagement with 269 perioperative medicine teams and/or dedicated long COVID clinics to identify strategies 270 for optimal risk reduction and provide objective assessment of physiologic recovery prior 271 to proceeding with surgery. At our institution, all patients with a history of 272 moderate/severe disease are recommended to be referred to preoperative clinic for 273 assessment prior to procedure to assess for recovery and help collaboratively 274 determine the optimal timing for surgery. Developing and applying machine 275 learning/artificial intelligence tools using the N3C Data Enclave are active areas of work

in our group to help provide more specific guidance for patients with a history of
 moderate or severe SARS-CoV-2 infection.

278 There are several limitations to our study that must be carefully considered when 279 interpreting the results. The use of electronic health record data within N3C Data Enclave may introduce biases that are well-described in prior studies¹⁴. Methods 280 281 specific to N3C can help manage several of these through rigorous data 282 standardization, a highly engaged user community, and a centralized platform for handling all data-related tasks including extraction, processing, and analyses. Another 283 284 source of bias is the selection of patients to undergo surgery after recovering from a 285 prior COVID-19 infection. Detailed information on preoperative evaluation, indications, 286 and rationale for proceeding with surgery prior to 7 weeks in patients with prior COVID-287 19 is not available. Additionally, we were unable to directly measure the association 288 between SARS-CoV-2 variants and outcomes—though, this likely is indirectly 289 accounted for in analyses that include severity. Despite these potential shortcomings, 290 leveraging the largest COVID-19-specific national data provides a unique opportunity to 291 help guide the management of patients with previous SARS-CoV-2 infections 292 undergoing elective surgery.

In conclusion, prior COVID-19 infection is a risk factor for adverse postoperative
outcomes following major inpatient elective surgery. The magnitude and duration of this
risk is dependent on the severity of COVID-19 infection and is reduced in vaccinated
patients. As the pandemic transitions to an endemic phase, the results of this study
emphasize a one-sized-fits-all approach to risk stratification in this patient population

can lead to unnecessary surgical delays, and consensus guidelines should be updated to include consideration of COVID-19 disease severity and vaccination status.

310 **REFERENCES**

- 3111.Johns Hopkins Coronavirus Resource Center. https://coronavirus.jhu.edu/us-312map. Accessed.
- EI-Boghdadly K, Cook TM, Goodacre T, et al. SARS-CoV-2 infection, COVID-19
 and timing of elective surgery: A multidisciplinary consensus statement on behalf
 of the Association of Anaesthetists, the Centre for Peri-operative Care, the
 Federation of Surgical Specialty Associations, the Royal College of Anaesthetists
- and the Royal College of Surgeons of England. *Anaesthesia*. 2021;76(7):940 946.
- Collaborative CO. Outcomes and Their State-level Variation in Patients
 Undergoing Surgery With Perioperative SARS-CoV-2 Infection in the USA: A
 Prospective Multicenter Study. *Ann Surg.* 2022;275(2):247-251.
- 4. Collaborative CO. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. *Lancet.* 2020;396(10243):27-38.
- Deng JZ, Chan JS, Potter AL, et al. The Risk of Postoperative Complications
 After Major Elective Surgery in Active or Resolved COVID-19 in the United
 States. Ann Surg. 2022;275(2):242-246.
- Verhagen NB, Koerber NK, Szabo A, et al. Vaccination Against SARS-CoV-2
 Decreases Risk of Adverse Events in Patients who Develop COVID-19 Following
 Cancer Surgery. Ann Surg Oncol. 2022:1-4.
- 7. Collaborative CO, GlobalSurg C. Timing of surgery following SARS-CoV-2
 infection: an international prospective cohort study. *Anaesthesia*. 2021;76(6):748758.
- SenthilKumar G, Verhagen NB, Sheriff SA, et al. Preoperative SARS-CoV-2
 Infection Increases Risk of Early Postoperative Cardiovascular Complications
 Following Non-Cardiac Surgery. *American Journal of Physiology Heart and Circulatory Physiology*. 2023;Accepted. In Press.
- Al Ani A, Tahtamoni R, Mohammad Y, Al-Ayoubi F, Haider N, Al-Mashhadi A.
 Impacts of severity of Covid-19 infection on the morbidity and mortality of surgical patients. *Ann Med Surg (Lond).* 2022;79:103910.
- Haendel MA, Chute CG, Bennett TD, et al. The National COVID Cohort
 Collaborative (N3C): Rationale, design, infrastructure, and deployment. *J Am Med Inform Assoc.* 2021;28(3):427-443.
- Characterisation WHOWGotC, Management of C-i. A minimal common outcome
 measure set for COVID-19 clinical research. *Lancet Infect Dis.* 2020;20(8):e192 e197.
- Bennett TD, Moffitt RA, Hajagos JG, et al. Clinical Characterization and
 Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using
 Data From the US National COVID Cohort Collaborative. *JAMA Netw Open.*2021;4(7):e2116901.
- ASA and APSF Joint Statement on Elective Surgery/Procedures and Anesthesia
 for Patients after COVID-19 Infection. 2022. <u>https://www.asahq.org/about-asa/newsroom/news-releases/2022/02/asa-and-apsf-joint-statement-on-elective-</u>
- 354 <u>surgery-procedures-and-anesthesia-for-patients-after-covid-19-infection</u>.

Verheij RA, Curcin V, Delaney BC, McGilchrist MM. Possible Sources of Bias in
 Primary Care Electronic Health Record Data Use and Reuse. *J Med Internet Res.* 2018;20(5):e185.

359 TABLES AND FIGURES

Table 1. Patient characteristics and 30-day postoperative adverse outcomes in

361 patients with and without preoperative COVID-19

Characteristics	No Hx of COVID-19 (N = 349,676), No. (%)	Hx of COVID-19 (N = 37,354), No. (%)	P value			
Patient Characteristics						
Age, years						
Median, (Q1-Q3)	63 (52, 72)	61 (49, 70)	<0.001			
18-29	15166 (4.3%)	1625 (4.4%)	<0.001			
30-49	60828 (17%)	7734 (21%)				
50-64	111160 (32%)	12838 (34%)				
65+	162522 (46%)	15157 (41%)				
Sex			<0.001			
Female	190052 (54%)	‡20952 (≈56%)				
Male	159505 (46%)	‡16399 (≈44%)				
Missing or Unknown	119 (<0.1%)	20 or fewer				
Race and Ethnicity	, , ,		<0.001			
Non-Hispanic White	257334 (74%)	25833 (69%)				
Non-Hispanic Black		4867 (13%)				
Non-Hispanic Asian		810 (2.2%)				
Hispanic	· · · · ·	3625 (9.1%)				
Other or Unknown	19930 (5.7%)	2403 (6.4%)				
Smoking Status			< 0.001			
Nonsmoker	304141 (86%)	33151 (89%)				
Current or Former						
Smoker	47716 (14%)	4203 (11%)				
Charlson Comorbidity Index (CCI)			<0.001			
0	72432 (21%)	6772 (18%)				
1	42341 (12%)	4412 (12%)				
2	63704 (18%)	6343 (17%)				
3	38900 (11%)	4275 (11%)				
4+	132299 (38%)	15552 (42%)				
Comorbidities						
CKD	22374 (6.4%)	3862 (10%)	<0.001			
CHF	20816 (6.0%)	3454 (9.2%)	< 0.001			
COPD	21089 (6.0%)	3134 (8.4%)	< 0.001			
Coronary Artery Disease	39221 (11%)	5852 (16%)	<0.001			
Depression	35956 (10%)	5875 (16%)	<0.001			
Diabetes	41584 (12%)	7144 (19%)	<0.001			
GERD	58830 (17%)	9432 (25%)	<0.001			

100981 (29%)	14669 (39%)	<0.001
5730 (1.6%)	977 (2.6%)	<0.001
51446 (15%)	8920 (24%)	<0.001
		0.058
134385 (38%)	14364 (38%)	
166702 (48%)	17642 (47%)	
48589 (14%)	5348 (14%)	
		<0.001
48441 (14%)	5381 (14%)	
301235 (86%)	31973 (86%)	
postoperative adverse	outcomes	
75075 (21.5%)	8493 (22.7%)	<0.001
4791 (1.4%)	666 (1.8%)	<0.001
38175 (11%)	4248 (11%)	0.008
73555 (21%)	8257 (22%)	<0.001
9089 (2.6%)	1020 (2.7%)	0.13
34326 (9.8%)	3752 (10%)	0.16
4648 (1.3%)	532 (1.4%)	0.13
9623 (2.8%)	1093 (2.9%)	0.053
4296 (1.2%)	519 (1.4%)	0.008
22488 (6.4%)	2592 (6.9%)	<0.001
18862 (5.4%)	2017 (5.4%)	0.97
10244 (2.9%)	1188 (3.2%)	0.007
9662 (2.8%)	1045 (2.8%)	0.71
	5730 (1.6%) 51446 (15%) 134385 (38%) 166702 (48%) 48589 (14%) 48589 (14%) 48441 (14%) 301235 (86%) postoperative adverse 75075 (21.5%) 4791 (1.4%) 38175 (11%) 73555 (21%) 9089 (2.6%) 34326 (9.8%) 4648 (1.3%) 9623 (2.8%) 4296 (1.2%) 22488 (6.4%) 18862 (5.4%) 10244 (2.9%)	5730 (1.6%) $977 (2.6%)$ $51446 (15%)$ $8920 (24%)$ $134385 (38%)$ $14364 (38%)$ $166702 (48%)$ $17642 (47%)$ $48589 (14%)$ $5348 (14%)$ $48441 (14%)$ $5381 (14%)$ $301235 (86%)$ $31973 (86%)$ $postoperative adverse outcomes$ $75075 (21.5%)$ $8493 (22.7%)$ $4791 (1.4%)$ $666 (1.8%)$ $38175 (11%)$ $4248 (11%)$ $73555 (21%)$ $8257 (22%)$ $9089 (2.6%)$ $1020 (2.7%)$ $34326 (9.8%)$ $3752 (10%)$ $4648 (1.3%)$ $532 (1.4%)$ $9623 (2.8%)$ $1093 (2.9%)$ $4296 (1.2%)$ $519 (1.4%)$ $22488 (6.4%)$ $2592 (6.9%)$ $18862 (5.4%)$ $2017 (5.4%)$ $10244 (2.9%)$ $1188 (3.2%)$


To comply with N3C policy, counts below 20 are displayed as <20 and additional
 values were skewed by up to 5 in order to render it impossible to back-calculate
 precise counts in the 'Missing or Unknown' category. Hx: history; CKD: chronic
 kidney disease; CHF: congestive heart failure; COPD: chronic obstructive
 pulmonary disease; GERD: gastroesophageal reflux disease.

368

369

Figure 1. Multivariable regression assessing the association between prior history of
 COVID-19 and composite 30-day postoperative adverse event. Hx: history; CCI:
 Charlson Comorbidity Index; aOR: adjusted odds ratio (with 95% confidence interval).






375 376

Figure 2. Multivariable regression assessing the association between timing of infection
 relative to surgery and 30-day postoperative adverse events. All models adjusted for
 age, sex, race and ethnicity, smoking status, comorbid disease, and relative risk of
 surgery. aOR: adjusted odds ratio (with 95% confidence interval).

382



385

505

Figure 3. Multivariable regression assessing the association between COVID-19

disease severity and 30-day postoperative adverse outcomes. All models adjusted for

389 age, sex, race and ethnicity, smoking status, comorbid disease, and relative risk of

390 surgery. aOR: adjusted odds ratio (with 95% confidence interval).

391





Figure 4. The interplay between timing of surgery and COVID-19 disease severity in
influencing odds of composite 30-day postoperative adverse events. All models
adjusted for age, sex, race and ethnicity, smoking status, Charlson Comorbidity Index,
and relative risk of surgery. aOR: adjusted odds ratio (with 95% confidence interval).


398



399

Figure 5. Multivariable regression assessing the association between full vaccination in
 patients with a history of COVID-19 and 30-day postoperative adverse events. All
 models adjusted for age, sex, race and ethnicity, smoking status, Charlson Comorbidity
 Index, and relative risk of surgery. aOR: adjusted odds ratio (with 95% confidence
 interval).

406





409

411 SUPPLEMENTARY DATA

412

413 Supplemental Table 1: Surgical Procedures and associated risk

414

Procedure Name	Surgery N=387,030 (%)	SNOMED Code
Low Risk		
Hip Arthroplasty	5480 (1.4%)	52734007
Knee Arthroplasty	6034 (1.6%)	609588000
Laminectomy	44462 (11%)	387731002
Mastectomy	75714 (20%)	69031006
Prostatectomy	17059 (4.4%)	90470006
Medium Risk		
Aortic Aneurysm Repair	4881 (1.3%)	233370007
Colectomy	46059 (12%)	23968004
Craniectomy	29201 (7.5%)	36910002
Gastrectomy	7903 (2.0%)	53442002
Lung Excision	17353 (4.5%)	119746007
Spinal Arthrodesis	78947 (20%)	55705006
High Risk		
Coronary Artery Bypass	37492 (9.7%)	232717009
Graft		
Esophagectomy	1538 (0.4%)	45900003
Hepatectomy	8495 (2.2%)	107963000
Pancreatectomy	6412 (1.7%)	33149006

415

416

418 Supplemental Table 2: Patient comorbidities

419

Preoperative Comorbidities	SNOMED Codes
Chronic Kidney Disease	709044004
Chronic Obstructive Pulmonary Disease	13645005
Coronary Artery Disease	53741008
Depression	370143000
Diabetes	73211009
Gastroesophageal Reflux Disease	235595009
Heart Failure	84114007
Hypertension	59621000
Liver Disease	328383001
Obesity	414916001

420

422 Supplemental Table 3: Postoperative Complications

423

Postoperative Complications	SNOMED Codes	
Acute Myocardial Infarction	57054005	
Cardiac Arrhythmia	698247007	
Deep Vein Thrombosis	128053003	
Pneumonia	233604007	
Pulmonary Embolism	59282003	
Renal Failure	42399005	
Respiratory Failure	409622000	
Sepsis	91302008	
Urinary Tract Infection	68566005	

424

425

Supplemental Table 4. Comparison of 30-day postoperative adverse events based

on surgical timing relative to COVID-19

Outcomes	No History of COVID-19 (N = 352,947)	0–4 Weeks Post- COVID-19 (N = 7,425)	4–8 Weeks Post- COVID-19 (N = 3,936)	8–12 Weeks Post COVID-19 (N = 2,604)	12+ Weeks Post COVID-19 (N = 23,389)	P value
Mortality	4791 (1.4%)	246 (3.3%)	83 (2.1%)	47 (1.8%)	290 (1.2%)	<0.001
LOS	2 (0, 6)	4 (1, 8)	2 (0, 6)	3 (0, 6)	2 (0, 5)	<0.001
Hospital Readmission Any Non-Fatal	38175 (11%)	848 (11%) 1914	458 (12%)	318 (12%)	2622 (11%)	0.057
Complication	73555 (21%)	(26%)	890 (23%)	625 (24%)	4828 (21%)	<0.001
Acute Myocardial Infarction	9089 (2.6%)	271 (3.6%)	100 (2.5%)	57 (2.2%)	592 (2.5%)	<0.001
Cardiac Arrhythmia	34326 (9.8%)	803 (11%)	409 (10%)	286 (11%)	2254 (9.6%)	0.006
Deep Vein Thrombosis	4648 (1.3%)	142 (1.9%)	57 (1.4%)	46 (1.8%)	287 (1.2%)	<0.001
Pneumonia Pulmonary	9623 (2.8%)	348 (4.7%)	131 (3.3%)	95 (3.6%)	519 (2.2%)	<0.001
Embolism	4296 (1.2%)	137 (1.8%)	58 (1.5%)	35 (1.3%)	289 (1.2%)	<0.001
Renal Failure	22488 (6.4%)	654 (8.8%)	288 (7.3%)	204 (7.8%)	1446 (6.2%)	<0.001
Respiratory Failure	18862 (5.4%)	655 (8.8%)	197 (5.0%)	164 (6.3%)	1001 (4.3%)	<0.001
Sepsis	10244 (2.9%)	346 (4.7%)	134 (3.4%)	95 (3.6%)	613 (2.6%)	<0.001
Urinary Tract Infection	9662 (2.8%)	208 (2.8%)	110 (2.8%)	88 (3.4%)	639 (2.7%)	0.43

432 **Supplemental Table 5.** Multivariable regression assessing the impact of timing of

433 infection relative to surgery on risk on composite and specific 30-day postoperative

434 adverse outcomes. All models adjusted for age, sex, race and ethnicity, smoking status,

435 and relative risk of surgery.

436

	0–4 weeks (N = 7,425)		4–8 weeks (N = 3,936)		8–12 weeks (N = 2,604)		12+ Weeks (N = 23,389)	
Composite 30-day			-				-	
postoperative	1.27	[1.20-1.35]	1.14	[1.05-1.24]	1.16	[1.05-1.28]	1.01	[0.98-1.05]
outcome		1		1		1		1
Mortality	2.34	[2.05-2.67]	1.57	[1.25-1.95]	1.22	[0.90-1.62]	0.92	[0.81-1.03]
Composite Non-								
fatal Complications	1.22	[1.15-1.29]	1.10	[1.01-1.20]	1.14	[1.03-1.26]	1.01	[0.98-1.05]
Hospital Readmission	0.99	[0.92-1.07]	1.02	[0.92-1.13]	1.06	[0.94-1.19]	1.01	[0.97-1.05]
Myocardial Infarction	1.13	[0.99-1.29]	0.93	[0.75-1.14]	0.73	[0.55-0.96]	1.06	[0.96-1.15]
Cardiac Arrhythmia	1.04	[0.96-1.13]	1.11	[1.00-1.24]	1.15	[1.00-1.31]	1.09	[1.04-1.15]
Deep Vein	1							
Thrombosis	1.33	[1.12-1.57]	1.04	[0.79-1.34]	1.21	[0.89-1.61]	0.88	[0.78-0.99]
Pneumonia	1.60	[1.43-1.79]	1.21	[1.01-1.44]	1.24	[1.00-1.52]	0.81	[0.74-0.88]
Pulmonary Embolism	1.44	[1.20-1.70]	1.17	[0.89-1.50]	1.01	[0.71-1.39]	0.96	[0.85-1.08]
Renal Failure	1.28	[1.17-1.39]	1.13	[0.99-1.27]	1.12	[0.96-1.30]	0.94	[0.89-1.00]
Respiratory Failure	1.53	[1.40-1.66]	0.90	[0.77-1.04]	1.09	[0.92-1.28]	0.80	[0.74-0.85]
Sepsis	1.52	[1.36-1.69]	1.14	[0.95-1.36]	1.15	[0.92-1.40]	0.87	[0.80-0.94]
Urinary Tract Infection	1.01	[0.87-1.15]	1.02	[0.84-1.23]	1.17	[0.94-1.44]	0.97	[0.90-1.05]
127	1.01		1.02	[0.04 1.20]	1.17		0.07	[0.00 1.00]

437

439 Supplemental Table 6. Comparison of specific 30-day postoperative adverse

440 events based on COVID-19 Severity.

441

Postoperative Complications	No History of COVID-19 (N = 351,857)	Mild Outpatient WHO Severity 1–3 (N = 31,677)	Moderate Hospitalized without invasive ventilation WHO Severity 4–6 (N= 5,009)	Severe Hospitalized with invasive ventilation or ECMO WHO Severity 7–9 (N= 655)	P value
Mortality	4791 (1.4%)	403 (1.3%)	169 (3.4%)	94 (14%)	<0.001
LOS	2 (0, 6)	2 (0, 5)	4 (1, 9)	12 (4, 29)	<0.001
Hospital Readmission	38175 (11%)	3293 (10%)	832 (17%)	121 (18%)	<0.001
Any Non-Fatal Complication	73555 (21%)	6110 (19%)	1746 (35%)	396 (60%)	<0.001
Acute Myocardial Infarction	9089 (2.6%)	723 (2.3%)	243 (4.9%)	53 (8.1%)	<0.001
Cardiac Arrhythmia	34326 (9.8%)	2856 (9.0%)	751 (15%)	142 (22%)	<0.001
Deep Vein Thrombosis	4648 (1.3%)	364 (1.1%)	126 (2.5%)	42 (6.4%)	<0.001
Pneumonia	9623 (2.8%)	704 (2.2%)	249 (5.0%)	138 (21%)	<0.001
Pulmonary Embolism	4296 (1.2%)	388 (1.2%)	99 (2.0%)	32 (4.9%)	<0.001
Renal Failure	22488 (6.4%)	1822 (5.8%)	588 (12%)	180 (27%)	<0.001
Respiratory Failure	18862 (5.4%)	1338 (4.2%)	448 (8.9%)	228 (35%)	<0.001
Sepsis	10244 (2.9%)	764 (2.4%)	271 (5.4%)	151 (23%)	<0.001
Urinary Tract Infection	9662 (2.8%)	791 (2.5%)	214 (4.3%)	39 (6.0%)	<0.001

443 **Supplemental Table 7.** Multivariable regression assessing the impact of COVID-19

disease severity on composite and specific 30-day postoperative adverse outcomes. All

445 models adjusted for age, sex, race and ethnicity, smoking status, and relative risk of 446 surgery.

447

	Mild (N = 31,677)	Moderate (N = 5,009)	Severe (N = 655)
Composite 30-day postoperative outcome	0.96 [0.93-1.00]	1.52 [1.43-1.62]	4.76 [4.01-5.68]
Mortality	1.00 [0.90-1.11]	1.77 [1.51-2.07]	7.49 [5.93-9.35]
Composite Non- fatal Complications	0.96 [0.93-0.99]	1.47 [1.38-1.57]	4.08 [3.44-4.84]
Hospital Readmission	0.96 [0.92-1.00]	1.26 [1.17-1.36]	1.20 [0.98-1.46]
Myocardial Infarction	0.94 [0.86-1.02]	1.31 [1.13-1.50]	2.02 [1.46-2.73]
Cardiac Arrhythmia	1.03 [0.98-1.07]	1.27 [1.17-1.38]	2.02 [1.64-2.47]
Deep Vein Thrombosis	0.87 [0.78-0.97]	1.37 [1.13-1.63]	3.01 [2.16-4.08]
Pneumonia	0.85 [0.79-0.92]	1.30 [1.14-1.48]	5.53 [4.53-6.70]
Pulmonary Embolism	1.01 [0.91-1.12]	1.19 [0.96-1.45]	2.56 [1.75-3.60]
Renal Failure	0.93 [0.88-0.98]	1.28 [1.17-1.40]	3.24 [2.69-3.89]
Respiratory Failure	0.82 [0.77-0.87]	1.20 [1.08-1.32]	5.71 [4.81-6.76]
Sepsis	0.85 [0.78-0.91]	1.33 [1.17-1.51]	5.91 [4.88-7.12]
Urinary Tract Infection	0.93 [0.86-1.00]	1.25 [1.08-1.43]	1.72 [1.22-2.36]

448

449

451 **Supplemental Table 8.** Comparison of specific 30-day postoperative adverse events

452 based on vaccination in patients with COVID-19.

Postoperative Complications	Non-Fully Vaccinated (N = 31,973), No. (%)	Fully Vaccinated (N = 5,381), No. (%)	P value
Mortality	585 (1.8%)	81 (1.5%)	0.11
LOS	2 (0, 6)	3 (0, 6)	0.014
Hospital Readmission	3644 (11%)	604 (11%)	0.73
Any Non-Fatal Complication	7072 (22%)	1185 (22%)	0.89
Acute Myocardial Infarction	892 (2.8%)	128 (2.4%)	0.10
Cardiac Arrhythmia	3172 (9.9%)	580 (11%)	0.056
Deep Vein Thrombosis	465 (1.5%)	67 (1.2%)	0.26
Pneumonia	970 (3.0%)	123 (2.3%)	0.003
Pulmonary Embolism	434 (1.4%)	85 (1.6%)	0.22
Renal Failure	2245 (7.0%)	347 (6.4%)	0.13
Respiratory Failure	1792 (5.6%)	225 (4.2%)	<0.001
Sepsis	1042 (3.3%)	146 (2.7%)	0.039
Urinary Tract Infection	873 (2.7%)	172 (3.2%)	0.061

453

454

4 - -

457 **DISCLAIMER**

- 458 The N3C Publication committee confirmed that this manuscript (MSID: 1004.67) is in
- 459 accordance with N3C data use and attribution policies; however, the content is solely the
- 460 responsibility of the authors and does not necessarily represent the official views of the NIH.
- 461 Authorship was determined using ICMJE recommendations.
- 462

463 **ACKNOWLEDGEMENT**

- 464 The analyses described in this publication were conducted under the DUR RP-A39709 and IRB
- 465 #PRO00042159 with data or tools accessed through the NCATS N3C Data Enclave
- 466 covid.cd2h.org/enclave and supported by CD2H The National COVID Cohort Collaborative
- 467 (N3C) IDeA CTR Collaboration 3U24TR002306-04S2 NCATS U24 TR002306. The project
- described was supported by the National Center for Advancing Translational Sciences, National
- 469 Institutes of Health, Award Number UL1 TR001436 and 3UL1TR001436-08S3. Additional
- 470 funding support provided by Advancing a Healthier Wisconsin Endowment. This research was
- 471 possible because of the patients whose information is included within the data from participating
- 472 organizations (covid.cd2h.org/dtas) and the organizations and scientists (covid.cd2h.org/duas)
- 473 who have contributed to the on-going development of this community resource
- 474 (https://doi.org/10.1093/jamia/ocaa196).
- 475
- 476 We gratefully acknowledge the following core contributors to N3C:
- 477 Adam B. Wilcox, Adam M. Lee, Alexis Graves, Alfred (Jerrod) Anzalone, Amin Manna, Amit
- 478 Saha, Amy Olex, Andrea Zhou, Andrew E. Williams, Andrew Southerland, Andrew T. Girvin,
- 479 Anita Walden, Anjali A. Sharathkumar, Benjamin Amor, Benjamin Bates, Brian Hendricks,
- 480 Brijesh Patel, Caleb Alexander, Carolyn Bramante, Cavin Ward-Caviness, Charisse Madlock-
- 481 Brown, Christine Suver, Christopher Chute, Christopher Dillon, Chunlei Wu, Clare Schmitt, Cliff
- 482 Takemoto, Dan Housman, Davera Gabriel, David A. Eichmann, Diego Mazzotti, Don Brown,
- Eilis Boudreau, Elaine Hill, Elizabeth Zampino, Emily Carlson Marti, Emily R. Pfaff, Evan
 French, Farrukh M Koraishy, Federico Mariona, Fred Prior, George Sokos, Greg Martin, Harold
- 485 Lehmann, Heidi Spratt, Hemalkumar Mehta, Hongfang Liu, Hythem Sidky, J.W. Awori Hayanga,
- 486 Jami Pincavitch, Jaylyn Clark, Jeremy Richard Harper, Jessica Islam, Jin Ge, Joel Gagnier, Joel
- 487 H. Saltz, Joel Saltz, Johanna Loomba, John Buse, Jomol Mathew, Joni L. Rutter, Julie A.
- 488 McMurry, Justin Guinney, Justin Starren, Karen Crowley, Katie Rebecca Bradwell, Kellie M.
- Walters, Ken Wilkins, Kenneth R. Gersing, Kenrick Dwain Cato, Kimberly Murray, Kristin
 Kostka, Lavance Northington, Lee Allan Pyles, Leonie Misguitta, Lesley Cottrell, Lili Portilla,
- 491 Mariam Deacy, Mark M. Bissell, Marshall Clark, Mary Emmett, Mary Morrison Saltz, Matvey B.
- 492 Palchuk, Melissa A. Haendel, Meredith Adams, Meredith Temple-O'Connor, Michael G. Kurilla,
- 493 Michele Morris, Nabeel Qureshi, Nasia Safdar, Nicole Garbarini, Noha Sharafeldin, Ofer Sadan,
- 494 Patricia A. Francis, Penny Wung Burgoon, Peter Robinson, Philip R.O. Payne, Rafael Fuentes,
- 495 Randeep Jawa, Rebecca Erwin-Cohen, Rena Patel, Richard A. Moffitt, Richard L. Zhu, Rishi
- 496 Kamaleswaran, Robert Hurley, Robert T. Miller, Saiju Pyarajan, Sam G. Michael, Samuel
- 497 Bozzette, Sandeep Mallipattu, Satyanarayana Vedula, Scott Chapman, Shawn T. O'Neil, Soko
- 498 Setoguchi, Stephanie S. Hong, Steve Johnson, Tellen D. Bennett, Tiffany Callahan, Umit
- Topaloglu, Usman Sheikh, Valery Gordon, Vignesh Subbian, Warren A. Kibbe, Wenndy
- 500 Hernandez, Will Beasley, Will Cooper, William Hillegass, Xiaohan Tanner Zhang. Details of
- 501 contributions available at covid.cd2h.org/core-contributors
- 502
- 503 The following institutions whose data is released or pending:
- 504 Available: Advocate Health Care Network UL1TR002389: The Institute for Translational
- 505 Medicine (ITM) Boston University Medical Campus UL1TR001430: Boston University
- 506 Clinical and Translational Science Institute Brown University U54GM115677: Advance
- 507 Clinical Translational Research (Advance-CTR) Carilion Clinic UL1TR003015: iTHRIV

508 Integrated Translational health Research Institute of Virginia • Charleston Area Medical Center 509 — U54GM104942: West Virginia Clinical and Translational Science Institute (WVCTSI) • 510 Children's Hospital Colorado — UL1TR002535: Colorado Clinical and Translational Sciences 511 Institute • Columbia University Irving Medical Center - UL1TR001873: Irving Institute for 512 Clinical and Translational Research • Duke University — UL1TR002553: Duke Clinical and 513 Translational Science Institute • George Washington Children's Research Institute — 514 UL1TR001876: Clinical and Translational Science Institute at Children's National (CTSA-CN) • 515 George Washington University — UL1TR001876: Clinical and Translational Science Institute at 516 Children's National (CTSA-CN) • Indiana University School of Medicine — UL1TR002529: Indiana Clinical and Translational Science Institute • Johns Hopkins University -517 518 UL1TR003098: Johns Hopkins Institute for Clinical and Translational Research • Lovola 519 Medicine — Loyola University Medical Center • Loyola University Medical Center — 520 UL1TR002389: The Institute for Translational Medicine (ITM) • Maine Medical Center — 521 U54GM115516: Northern New England Clinical & Translational Research (NNE-CTR) Network • 522 Massachusetts General Brigham — UL1TR002541: Harvard Catalyst • Mayo Clinic Rochester 523 - UL1TR002377: Mayo Clinic Center for Clinical and Translational Science (CCaTS) • Medical 524 University of South Carolina - UL1TR001450: South Carolina Clinical & Translational 525 Research Institute (SCTR) • Montefiore Medical Center — UL1TR002556: Institute for Clinical 526 and Translational Research at Einstein and Montefiore • Nemours — U54GM104941: Delaware 527 CTR ACCEL Program • NorthShore University HealthSystem — UL1TR002389: The Institute for 528 Translational Medicine (ITM) • Northwestern University at Chicago — UL1TR001422: 529 Northwestern University Clinical and Translational Science Institute (NUCATS) • OCHIN - INV-530 018455: Bill and Melinda Gates Foundation grant to Sage Bionetworks • Oregon Health & 531 Science University — UL1TR002369: Oregon Clinical and Translational Research Institute • 532 Penn State Health Milton S. Hershey Medical Center — UL1TR002014: Penn State Clinical and 533 Translational Science Institute • Rush University Medical Center — UL1TR002389: The Institute 534 for Translational Medicine (ITM) • Rutgers, The State University of New Jersey -535 UL1TR003017: New Jersey Alliance for Clinical and Translational Science • Stony Brook 536 University — U24TR002306 • The Ohio State University — UL1TR002733: Center for Clinical 537 and Translational Science • The State University of New York at Buffalo — UL1TR001412: 538 Clinical and Translational Science Institute • The University of Chicago — UL1TR002389: The 539 Institute for Translational Medicine (ITM) • The University of Iowa — UL1TR002537: Institute for 540 Clinical and Translational Science • The University of Miami Leonard M. Miller School of 541 Medicine — UL1TR002736: University of Miami Clinical and Translational Science Institute • 542 The University of Michigan at Ann Arbor — UL1TR002240: Michigan Institute for Clinical and 543 Health Research • The University of Texas Health Science Center at Houston — 544 UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • The University of Texas 545 Medical Branch at Galveston — UL1TR001439: The Institute for Translational Sciences • The 546 University of Utah - UL1TR002538: Uhealth Center for Clinical and Translational Science • 547 Tufts Medical Center - UL1TR002544: Tufts Clinical and Translational Science Institute • 548 Tulane University — UL1TR003096: Center for Clinical and Translational Science • University 549 Medical Center New Orleans — U54GM104940: Louisiana Clinical and Translational Science 550 (LA CaTS) Center • University of Alabama at Birmingham — UL1TR003096: Center for Clinical 551 and Translational Science • University of Arkansas for Medical Sciences — UL1TR003107: 552 UAMS Translational Research Institute • University of Cincinnati — UL1TR001425: Center for 553 Clinical and Translational Science and Training • University of Colorado Denver, Anschutz 554 Medical Campus - UL1TR002535: Colorado Clinical and Translational Sciences Institute • 555 University of Illinois at Chicago — UL1TR002003: UIC Center for Clinical and Translational Science • University of Kansas Medical Center - UL1TR002366: Frontiers: University of 556 557 Kansas Clinical and Translational Science Institute • University of Kentucky — UL1TR001998: 558 UK Center for Clinical and Translational Science • University of Massachusetts Medical School

559 Worcester — UL1TR001453: The UMass Center for Clinical and Translational Science 560 (UMCCTS) • University of Minnesota — UL1TR002494: Clinical and Translational Science Institute • University of Mississippi Medical Center - U54GM115428: Mississippi Center for 561 562 Clinical and Translational Research (CCTR) • University of Nebraska Medical Center -563 U54GM115458: Great Plains IDeA-Clinical & Translational Research • University of North 564 Carolina at Chapel Hill — UL1TR002489: North Carolina Translational and Clinical Science 565 Institute • University of Oklahoma Health Sciences Center — U54GM104938: Oklahoma Clinical 566 and Translational Science Institute (OCTSI) • University of Rochester - UL1TR002001: UR 567 Clinical & Translational Science Institute • University of Southern California — UL1TR001855: 568 The Southern California Clinical and Translational Science Institute (SC CTSI) • University of 569 Vermont — U54GM115516: Northern New England Clinical & Translational Research (NNE-570 CTR) Network • University of Virginia — UL1TR003015: iTHRIV Integrated Translational health 571 Research Institute of Virginia • University of Washington - UL1TR002319: Institute of 572 Translational Health Sciences • University of Wisconsin-Madison — UL1TR002373: UW 573 Institute for Clinical and Translational Research • Vanderbilt University Medical Center — 574 UL1TR002243: Vanderbilt Institute for Clinical and Translational Research • Virginia 575 Commonwealth University — UL1TR002649: C. Kenneth and Dianne Wright Center for Clinical 576 and Translational Research • Wake Forest University Health Sciences — UL1TR001420: Wake 577 Forest Clinical and Translational Science Institute • Washington University in St. Louis -578 UL1TR002345: Institute of Clinical and Translational Sciences • Weill Medical College of Cornell 579 University — UL1TR002384: Weill Cornell Medicine Clinical and Translational Science Center • 580 West Virginia University — U54GM104942: West Virginia Clinical and Translational Science 581 Institute (WVCTSI) 582 Submitted: Icahn School of Medicine at Mount Sinai — UL1TR001433: ConduITS Institute for 583 Translational Sciences • The University of Texas Health Science Center at Tyler — 584 UL1TR003167: Center for Clinical and Translational Sciences (CCTS) • University of California, 585 Davis — UL1TR001860: UCDavis Health Clinical and Translational Science Center • University 586 of California, Irvine — UL1TR001414: The UC Irvine Institute for Clinical and Translational 587 Science (ICTS) • University of California, Los Angeles — UL1TR001881: UCLA Clinical 588 Translational Science Institute • University of California, San Diego — UL1TR001442: Altman 589 Clinical and Translational Research Institute • University of California, San Francisco — 590 UL1TR001872: UCSF Clinical and Translational Science Institute 591 Pending: Arkansas Children's Hospital — UL1TR003107: UAMS Translational Research 592 Institute • Baylor College of Medicine — None (Voluntary) • Children's Hospital of Philadelphia 593 — UL1TR001878: Institute for Translational Medicine and Therapeutics • Cincinnati Children's 594 Hospital Medical Center — UL1TR001425: Center for Clinical and Translational Science and 595 Training • Emory University — UL1TR002378: Georgia Clinical and Translational Science 596 Alliance • HonorHealth — None (Voluntary) • Lovola University Chicago — UL1TR002389: The Institute for Translational Medicine (ITM) • Medical College of Wisconsin — UL1TR001436: 597 598 Clinical and Translational Science Institute of Southeast Wisconsin • MedStar Health Research 599 Institute — UL1TR001409: The Georgetown-Howard Universities Center for Clinical and 600 Translational Science (GHUCCTS) • MetroHealth — None (Voluntary) • Montana State 601 University — U54GM115371: American Indian/Alaska Native CTR • NYU Langone Medical 602 Center — UL1TR001445: Langone Health's Clinical and Translational Science Institute • 603 Ochsner Medical Center — U54GM104940: Louisiana Clinical and Translational Science (LA 604 CaTS) Center • Regenstrief Institute — UL1TR002529: Indiana Clinical and Translational Science Institute • Sanford Research - None (Voluntary) • Stanford University -605 606 UL1TR003142: Spectrum: The Stanford Center for Clinical and Translational Research and 607 Education • The Rockefeller University — UL1TR001866: Center for Clinical and Translational 608 Science • The Scripps Research Institute — UL1TR002550: Scripps Research Translational 609 Institute • University of Florida — UL1TR001427: UF Clinical and Translational Science Institute

- University of New Mexico Health Sciences Center UL1TR001449: University of New Mexico
- 611 Clinical and Translational Science Center University of Texas Health Science Center at San
- 612 Antonio UL1TR002645: Institute for Integration of Medicine and Science Yale New Haven
- 613 Hospital UL1TR001863: Yale Center for Clinical Investigation